- Clinical Trials
- April 2024
- 80 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Report
- July 2023
- 135 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- July 2023
- 67 Pages
Global
From €3804EUR$3,950USD£3,271GBP
- Report
- October 2023
- 181 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1445EUR$1,500USD£1,242GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1204EUR$1,250USD£1,035GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1445EUR$1,500USD£1,242GBP
- Report
- October 2023
- 145 Pages
Global
From €3033EUR$3,150USD£2,609GBP
- Report
- June 2023
- 92 Pages
Asia Pacific
From €1445EUR$1,500USD£1,242GBP
- Report
- November 2021
- 159 Pages
Global
From €4093EUR$4,250USD£3,520GBP
- Report
- January 2022
- 200 Pages
Global
From €7223EUR$7,500USD£6,212GBP
- Report
- January 2022
- 60 Pages
Global
From €3804EUR$3,950USD£3,271GBP
- Report
- November 2018
- 106 Pages
Global
From €10588EUR$10,995USD£9,106GBP
- Report
- August 2022
- 324 Pages
Global
From €3698EUR$3,840USD£3,180GBP
The Opioid Dependence market is a subset of the Addiction Disorders Drugs market, which includes medications used to treat substance use disorders. Opioid Dependence medications are used to treat individuals with opioid use disorder, a condition characterized by compulsive opioid use despite negative consequences. These medications work by reducing cravings and withdrawal symptoms, and can be used as part of a comprehensive treatment plan. Common medications used to treat opioid dependence include buprenorphine, methadone, and naltrexone.
Companies in the Opioid Dependence market include Indivior, Reckitt Benckiser, Orexo, and Braeburn Pharmaceuticals. Show Less Read more
